Literature DB >> 14713791

Predicting quality of life after radical prostatectomy: results from CaPSURE.

Jim C Hu1, Eric P Elkin, David J Pasta, Deborah P Lubeck, Michael W Kattan, Peter R Carroll, Mark S Litwin.   

Abstract

PURPOSE: We investigated the usefulness of patient and tumor characteristics in predicting continence, potency, and physical and mental health 1 year after radical prostatectomy.
MATERIALS AND METHODS: We studied 372 men drawn from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE), a national, longitudinal cohort, who underwent radical prostatectomy alone for localized prostate cancer. Health related quality of life (HRQOL) was assessed before and 12 months after (range 9 to 15) surgery with the Physical and Mental Component Summaries of the RAND 36-Item Health Survey and the Sexual and Urinary Function scales of the UCLA Prostate Cancer Index. Covariates included clinical T stage, prostate specific antigen Gleason sum, age, race, income, education, relationship status, comorbidity and overall health self-rating. Chi-square and backward stepwise multivariate analysis identified differences between men who did and did not return to baseline HRQOL postoperatively. Return to baseline HRQOL score was set at 90% or greater for physical and mental health, 80% for continence and 75% for potency.
RESULTS: After 1 year 63%, 20%, 80% and 86% returned to baseline continence, potency, physical health and mental health, respectively. Men younger than 65 years were more likely to return to baseline continence, potency, and physical but not mental health. Univariate analyses also revealed several other characteristics to predict (p <0.05) better outcomes including household income greater than 30,000 US dollars (potency, physical health), fewer comorbidities (potency, physical health), and excellent or very good health self-rating (mental health). In multivariate analyses subjects younger than 65 years were more likely to return to baseline urinary (OR 1.8, p <0.01), sexual (OR 2.5, p <0.01) and physical health (OR 1.8, p = 0.03). Furthermore, subjects with no comorbidities were more likely to return to baseline physical health (OR 2.5, p = 0.01), while those with an excellent or very good baseline health self-rating were more likely to return to baseline mental health (OR 2.3, p = 0.01). Clinical T stage, prostate specific antigen and Gleason sum did not predict return to baseline HRQOL.
CONCLUSIONS: Younger patient age (less than 65) is associated with a greater likelihood of returning to baseline continence, potency and physical health after radical prostatectomy. In addition, patients who underwent radical prostatectomy without comorbidities and those with high health self-ratings are more likely to return to baseline physical and mental health, respectively. Preoperative tumor characteristics do not appear to be associated with regaining baseline HRQOL, suggesting that factors not measured in this model may be important in optimizing quality of life after radical prostatectomy.

Entities:  

Mesh:

Year:  2004        PMID: 14713791     DOI: 10.1097/01.ju.0000107964.61300.f6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  32 in total

1.  Assessing longitudinal quality of life in prostate cancer patients and their spouses: a multilevel modeling approach.

Authors:  Lixin Song; Laurel L Northouse; Thomas M Braun; Lingling Zhang; Bernadine Cimprich; David L Ronis; Darlene W Mood
Journal:  Qual Life Res       Date:  2010-10-08       Impact factor: 4.147

2.  Prediction of erectile function following treatment for prostate cancer.

Authors:  Mehrdad Alemozaffar; Meredith M Regan; Matthew R Cooperberg; John T Wei; Jeff M Michalski; Howard M Sandler; Larry Hembroff; Natalia Sadetsky; Christopher S Saigal; Mark S Litwin; Eric Klein; Adam S Kibel; Daniel A Hamstra; Louis L Pisters; Deborah A Kuban; Irving D Kaplan; David P Wood; Jay Ciezki; Rodney L Dunn; Peter R Carroll; Martin G Sanda
Journal:  JAMA       Date:  2011-09-21       Impact factor: 56.272

3.  Erectile function outcomes in the current era of anatomic nerve-sparing radical prostatectomy.

Authors:  Arthur L Burnett
Journal:  Rev Urol       Date:  2006

Review 4.  Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer.

Authors:  Vinay Prabhu; Ted Lee; Tyler R McClintock; Herbert Lepor
Journal:  Rev Urol       Date:  2013

5.  Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.

Authors:  Ryan K Berglund; Timothy A Masterson; Kinjal C Vora; Scott E Eggener; James A Eastham; Bertrand D Guillonneau
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

Review 6.  Incontinence after radical prostatectomy: Anything new in its management?

Authors:  Romain Caremel; Jacques Corcos
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

Review 7.  Penile rehabilitation: the evolutionary concept in the management of erectile dysfunction.

Authors:  Tariq S Hakky; Adam S Baumgarten; Justin Parker; Yin Zheng; Mike Kongnyuy; Daniel Martinez; Rafael E Carrion
Journal:  Curr Urol Rep       Date:  2014-04       Impact factor: 3.092

8.  Treatment-related toxicity and symptom-related bother following postoperative radiotherapy for prostate cancer.

Authors:  Michael Sia; George Rodrigues; Cynthia Menard; Andrew Bayley; Robert Bristow; Peter Chung; Mary Gospodarowicz; Michael Milosevic; Padraig Warde; Charles Catton
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

9.  Oncological and functional results of extraperitoneal laparoscopic radical prostatectomy.

Authors:  Tao Zheng; Xu Zhang; Xin Ma; Hong-Zhao Li; Jiang-Pin Gao; Wei Cai; Guang-Fu Chen; Jun Dong; Bao-Jun Wang; Tao-Ping Shi
Journal:  Oncol Lett       Date:  2012-05-30       Impact factor: 2.967

Review 10.  Post-prostatectomy incontinence: Etiology, evaluation, and management.

Authors:  Nirmish Singla; Ajay K Singla
Journal:  Turk J Urol       Date:  2014-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.